GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (NAS:SLS) » Definitions » Cyclically Adjusted Price-to-FCF

SELLAS Life Sciences Group (SELLAS Life Sciences Group) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


SELLAS Life Sciences Group Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Cyclically Adjusted Price-to-FCF Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SELLAS Life Sciences Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF falls into.



SELLAS Life Sciences Group Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

SELLAS Life Sciences Group's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, SELLAS Life Sciences Group's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.24/131.7762*131.7762
=-0.240

Current CPI (Mar. 2024) = 131.7762.

SELLAS Life Sciences Group Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -3,321.000 100.560 -4,351.939
201409 -2,783.500 100.428 -3,652.366
201412 -2,710.750 99.070 -3,605.667
201503 -2,314.800 99.621 -3,061.957
201506 -2,375.200 100.684 -3,108.688
201509 -1,901.400 100.392 -2,495.822
201512 -3,071.200 99.792 -4,055.530
201603 -2,203.667 100.470 -2,890.313
201606 -1,915.167 101.688 -2,481.838
201609 -1,744.000 101.861 -2,256.189
201612 2,506.500 101.863 3,242.571
201703 -152.120 102.862 -194.880
201706 -117.269 103.349 -149.525
201709 -745.615 104.136 -943.523
201712 132.600 104.011 167.997
201803 -45.403 105.290 -56.825
201806 -46.659 106.317 -57.832
201809 -40.127 106.507 -49.647
201812 -10.329 105.998 -12.841
201903 -11.166 107.251 -13.719
201906 -7.207 108.070 -8.788
201909 -0.892 108.329 -1.085
201912 -0.822 108.420 -0.999
202003 -1.072 108.902 -1.297
202006 -0.503 108.767 -0.609
202009 -0.431 109.815 -0.517
202012 0.330 109.897 0.396
202103 -0.690 111.754 -0.814
202106 -0.321 114.631 -0.369
202109 -0.370 115.734 -0.421
202112 -0.313 117.630 -0.351
202203 -0.450 121.301 -0.489
202206 -0.284 125.017 -0.299
202209 -0.279 125.227 -0.294
202212 -0.248 125.222 -0.261
202303 -0.515 127.348 -0.533
202306 -0.267 128.729 -0.273
202309 -0.243 129.860 -0.247
202312 -0.157 129.419 -0.160
202403 -0.240 131.776 -0.240

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SELLAS Life Sciences Group  (NAS:SLS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


SELLAS Life Sciences Group Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group (SELLAS Life Sciences Group) Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Executives
Angelos M. Stergiou director, officer: President and CEO C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583
Barbara A Wood officer: EVP, Gen. Counsel, Corp. Sec. 58 S SERVICE RD, MELVILLE NY 11747
John Thomas Burns officer: VP, Finance & Corp Controller 16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Robert Francomano officer: Chief Commercial Officer C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022
Nicholas J. Sarlis officer: Chief Medical Officer and SVP C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583
Stephen F Ghiglieri director C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David A Scheinberg director 325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
John Varian director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund` 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Equilibria Capital Management Ltd 10 percent owner O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08

SELLAS Life Sciences Group (SELLAS Life Sciences Group) Headlines

From GuruFocus